Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients...
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that the Ohio Bureau of Workers Compensation (BWC) has approved a change to its...
BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a specialty pharmaceutical company with a focus in pain management and addiction medicine,...
BioDelivery Sciences International, Inc. (BDSI) today reported financial results for the three and nine months ended September 30, 2017, and provided ...
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that it will report its third quarter 2017 financial results and host a conference...
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) participated in a round table meeting convened this week in Washington, D.C. by the U.S....
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that Dr. Mark A. Sirgo, Vice Chairman, President and Chief Executive Officer, will...
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced today that Health Canada has granted market authorization to formally transfer the...
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) presented three posters including results from an analysis of data which evaluated the...
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced today that at the end of 2017, Dr. Mark A. Sirgo will retire as BDSI's President...
BioDelivery Sciences International, Inc. (BDSI) today reported financial results for the three and six months ended June 30, 2017, and provided an...
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that it will report its second quarter 2017 financial results and host a conference ...
Today, BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a specialty pharmaceutical company with a focus in pain management and addiction...
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that Health Canada, the regulatory authority in Canada, has issued a Notice of...
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that it has signed an agreement with CVS/Caremark extending access to both BELBUCA® ...
BioDelivery Sciences International, Inc. (BDSI) today reported financial results for the first quarter ended March 31, 2017 and provided a corporate...
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that it will report its first quarter 2017 financial results and host a conference...
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that the U.S. Food and Drug Administration (FDA) has approved a Supplemental New...
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that Dr. Mark A. Sirgo, President and Chief Executive Officer, will present at the...
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that two important new patents were granted extending patent protection around all...
BioDelivery Sciences International, Inc. (BDSI) today reported financial results for the fourth quarter and full year ended December 31, 2016, and...
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced three data presentations from research surrounding BELBUCA® (buprenorphine) buccal...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.